The effectiveness of gastric injections of botulinum toxin-A (BTA) as primary treatment for obesity is not well known since results in literature are discrepant. Hence, we aimed to systematically review and meta-analyze the available data to assess the real effect of BTA therapy. We searched MEDLINE, Embase, Cochrane, SCOPUS, EBSCO, LILACS, and BVS. We considered eligible only randomized controlled trials enrolling obese patients comparing BTA versus saline injections. Our initial search identified 8811 records. Six studies fulfilled eligibility criteria. After critical appraisal, two articles were excluded and we meta-analyzed the remainder. The mean difference for absolute weight loss and BMI reduction were 0.12 [CI 95%, − 1.14, 1.38] and − 0.06 [95% CI, − 0.92, 0.81], respectively. Therefore, we concluded that treatment of obesity with BTA is not effective.
Dr. GALVAO NETO reports personal fees from APOLLO ENDOSURGERY, personal fees from FRACTYL LABS, personal fees from GI WINDOWS, personal fees from GI DYNAMICS, personal fees from ETHICOM ENDOSURGERY, personal fees from ALACER BIOMEDICA outside the submitted work. All the other authors have nothing to declare.
Ethical Approval Statement
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed Consent Statement
Does not apply.
National Task Force on the Prevention and Treatment of Obesity. Overweight, obesity, and health risk. Arch Intern Med. 2000;160(7):898–904.CrossRefGoogle Scholar
Douketis JD, Macie C, Thabane L, et al. Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice. Int J Obes (Lond). 2005;29(10):1153.CrossRefGoogle Scholar
Leslie WS, Hankey CR, Lean ME. Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review. QJM. 2007;100(7):395.CrossRefPubMedGoogle Scholar
Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342.CrossRefPubMedGoogle Scholar
Maggard MA, Shugarman LR, Suttorp M, et al. Meta-analysis: surgical treatment of obesity. Ann Intern Med. 2005;142(7):547.CrossRefPubMedGoogle Scholar
Roman S, Napoléon B, Mion F, et al. Intragastric balloon for “non-morbid” obesity: a retrospective evaluation of tolerance and efficacy. Obes Surg. 2004;14(4):539.CrossRefPubMedGoogle Scholar
Busetto L, Segato G, De Luca M, et al. Preoperative weight loss by intragastric balloon in super-obese patients treated with laparoscopic gastric banding: a case-control study. Obes Surg. 2004;14(5):671.CrossRefPubMedGoogle Scholar
Topazian M, Camilleri M, De La Mora-Levy J, et al. Endoscopic ultrasound-guided gastric botulinum toxin injections in obese subjects: a pilot study. Obes Surg. 2008 Apr;18(4):401–7.CrossRefPubMedPubMedCentralGoogle Scholar
Pero R, Coretti L, Lembo F. Botulinum toxin A for controlling obesity. Toxins (Basel) 2016 8(10).Google Scholar
Klobucar Majanovic S, Brozovic B, Stimac D. Bariatric endoscopy: current state of the art, emerging technologies, and challenges. Expert Rev Med Devices. 2017;14(2):149–59.CrossRefPubMedGoogle Scholar
Mittermair R, Keller C, Geibel J. Intragastric injection of botulinum toxin for the treatment of obesity. Obes Surg. 2007;17:732–6.CrossRefPubMedGoogle Scholar
Bang CS, Baik GH, Shin IS, et al. Effect of intragastric injection of botulinum toxin A for the treatment of obesity: a meta-analysis and meta-regression. Gastrointest Endosc. 2015;81(5):1141–9.e1–7.CrossRefPubMedGoogle Scholar
Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.Google Scholar
Gui D, Mingrone G, Valenza V, et al. Effect of botulinum toxin antral injection on gastric emptying and weight reduction in obese patients: a pilot study. Aliment Pharmacol Ther. 2006;23(5):675–80.CrossRefPubMedGoogle Scholar
Foschi D, Corsi F, Lazzaroni M, et al. Treatment of morbid obesity by intraparietogastric administration of botulinum toxin: a randomized, double-blind, controlled study. Int J Obes. 2007;31(4):707–12.Google Scholar
Topazian M, Camilleri M, Enders FT, et al. Gastric antral injections of botulinum toxin delay gastric emptying but do not reduce body weight. Clin Gastroenterol Hepatol. 2013;11(2):145–50.e1.CrossRefPubMedGoogle Scholar
Lal S, McLaughlin J, Barlow J, et al. Cholecystokinin pathways modulate sensations induced by gastric distension in humans. Am J Physiol Gastrointest Liver Physiol. 2004;287(1):G72–9.CrossRefPubMedGoogle Scholar
Geliebter A, Westreich S, Gage D. Gastric distention by balloon and test-meal intake. Am J Clin Nutr. 1988;48:592–4.PubMedGoogle Scholar
Genco A, Bruni T, Doldi SB, et al. BioEnterics Intragastric balloon: the Italian experience with 2,515 patients. Obes Surg. 2005;15(8):1161–4.CrossRefPubMedGoogle Scholar
Sallet JA, Marchesini JB, Paiva DS, et al. Brazilian multicenter study of the intragastric balloon. Obes Surg. 2004;14(7):991–8.CrossRefPubMedGoogle Scholar
Júnior AC, Savassi-Rocha PR, Coelho LG, et al. Botulinum A toxin injected into the gastric wall for the treatment of class III obesity: a pilot study. Obes Surg. 2006;16(3):335–43.CrossRefPubMedGoogle Scholar
Albani G, Petroni ML, Mauro A, et al. Safety and efficacy of therapy with botulinum toxin in obesity: a pilot study. J Gastroenterol. 2005;40(8):833–5.CrossRefPubMedGoogle Scholar
Lerner H, Whang J, Nipper R. Benefit-risk paradigm for clinical trial design of obesity devices: FDA proposal. Surg Endosc. 2013;27(3):702–7. Erratum in: Surg Endosc. 2013 Mar;27(3):708CrossRefPubMedGoogle Scholar
Foschi D, Lazaron M, Sangaletti O, et al. Effects of intramural administration of botulinum toxin A on gastric emptying and eating capacity in obese patients. Dig Liver Dis. 2008;40:667–72.CrossRefPubMedGoogle Scholar